secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anixa Biosciences Inc (ANIX)
CIK:        0000715446
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001493152-24-018170
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anixa expands Cleveland Clinic joint development to develop additional cancer vaccines
--------------------------------------------------------------------------------

- Anixa and Cleveland Clinic entered Joint Development and Option Agreement to develop vaccines for multiple cancers.
- Anixa to pay non-refundable option fee and development funding in three tranches; first due May 8, 2024.
- Option to obtain exclusive, royalty-bearing worldwide license to inventions developed under agreement.
- Builds on existing breast cancer (Phase 1 TNBC) and ovarian cancer vaccine programs with Cleveland Clinic.
- Research led by Dr. Thaddeus Stappenbeck and Dr. Justin Johnson at Cleveland Clinic.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/715446/000149315224018170/0001493152-24-018170-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/715446/000149315224018170/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-018170

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer